Clinical trials: Stomatognathic System
Primary Sjögren Syndrome, Dry Eye
Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome
The objective of this study is to evaluate the efficacy and safety of two strengths of Lacripep™ ophthalmic solution versus placebo administered three times daily for four weeks in subjects with a diagnosis of Dry Eye associated…
- Trial name
- NCT03226444
- Testing
- 0.005% Lacripep, 0.01% Lacripep
- Where
- 35 sites in United States
- Volunteers
- 204 people
- Sponsor
- TearSolutions, Inc.
Edentulous Jaw
A Clinical Study of the Eztetic Dental Implant System
This will be a prospective, observational multicenter study. All implants will be placed in the anterior maxilla or mandible and immediately loaded with a provisional prosthesis out of occlusion.
- Trial name
- RoseQuartz (NCT03917927)
- Testing
- Eztetic dental implant
- Where
- 4 sites in United States, Chile and 1 more
- Volunteers
- 82 people
- Sponsor
- ZimVie
Leukoplakia, Hairy, HIV Infections
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
- Trial name
- NCT00002026
- Testing
- Acyclovir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Head and Neck Cancer, Esophageal Cancer
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer
9 participants are expected to be enrolled for this open，single-armed clinical trial to evaluate the safety and efficacy of the recombinant herpes simplex virus Ⅰ, R130 in patients with relapsed/refractory head and neck cancer.
- Conditions
- Head and Neck Cancer, Esophageal Cancer, Otorhinolaryngologic Neoplasms, Ear Cancer
- Trial name
- NCT05830240
- Testing
- Recombinant oncolytic herpes simplex virus type 1 (R130)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Yunying Medical Technology
Candidiasis, Oral, HIV Infections
A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS
To compare the efficacy, safety, and tolerance of fluconazole single daily capsule for 14 days versus clotrimazole troche 5 x daily for 14 days in the treatment of oropharyngeal candidiasis in patients with AIDS.
- Trial name
- NCT00002282
- Testing
- Clotrimazole, Fluconazole
- Where
- 17 sites in United States
- Sponsor
- Pfizer
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Measles, Mumps
Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine
The present study will explore the immunogenicity of AVAXIM™ 80U-Pediatric in 12-13 months Turkish children and check if the administration of the MMR trivalent vaccine on the same day but at different site will interfere on…
- Conditions
- Measles, Mumps, Rubella, Hepatitis A
- Trial name
- NCT00313950
- Testing
- Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella, Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Advanced Malignancies
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose.
- Trial name
- NCT03474640
- Testing
- Part A, Part B
- Where
- 14 sites in United States
- Volunteers
- 184 people
- Sponsor
- TopAlliance Biosciences
Sloughing Skin, Mucosal Inflammation
A Study to Assess the Impact of a Non-SLS Toothpaste Upon Oral Mucosal Desquamation
This study is to compare the effect on oral mucosal desquamation of a non-SLS toothpaste and an SLS-containing toothpaste..
- Trial name
- NCT03598881
- Testing
- Treatment
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
Health, Subjective, Gastrointestinal Dysfunction
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
The LIFE-HOUSE research project is designed to evaluate the impact of a personalized lifestyle intervention program on functional capacity as an approach to quantitating health, and its relationship to well understood disease…
- Conditions
- Health, Subjective, Gastrointestinal Dysfunction, Cardiovascular Risk Factor, Autoimmune Diseases
- Trial name
- LIFE-HOUSE (NCT04005456)
- Testing
- Supplements and/or medical foods, Behavioral change support program, Food plan
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Metagenics, Inc.
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Periodontal Diseases
Development of a Molecular Diagnosing Platform for Monitoring Oral Hygiene in Diabetic Patients
More than ninety percent of adults in Taiwan are suspected to carry periodontal disease, which causes bad breath, swollen and bleeding gums, plaque and even tooth loss.
- Trial name
- NCT03351530
- Where
- Taiwan
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- General Biologicals Corporation
Dry Eye Syndromes, ATD
Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease
The objective of this study is to evaluate the safety and effectiveness of Viveye OMNS non-invasive treatment for management of the signs and symptoms of severe dry eye disease.
- Conditions
- Dry Eye Syndromes, ATD, Sjogren's Syndrome
- Trial name
- OMNS (NCT04143841)
- Testing
- Viveye OMNS treatment
- Where
- 3 sites in Israel
- Volunteers
- 50 people
- Sponsor
- Epitech Mag Ltd.
Facial Paralysis
A Study of NTX-001 in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
This study involves the use of an Investigational Product called NTX-001. It is a product used in the repair of nerve injuries. It is used in the operating room.
- Trial name
- NCT05293522
- Testing
- NTX-001
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Neuraptive Therapeutics Inc.
Dry Eye Disease, Sjögren Syndrome
Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome
This study will examine the efficacy and safety of tivanisiran sodium eye drops versus vehicle after a 2-week run-in phase when dosed once daily for 3 months in subjects with signs and symptoms of dry eye disease (DED) due to…
- Trial name
- NCT04819269
- Testing
- Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
- Where
- 46 sites in United States, Spain
- Volunteers
- 203 people
- Sponsor
- Sylentis, S.A.
Oral Mucositis, Lymphoma
Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT
Evaluate the efficacy and safety for the prevention of oral mucositis and PK of MIT-001 for lymphoma or multiple myeloma patients receiving conditioning chemotherapy for autologous hematopoietic stem cell…
- Conditions
- Oral Mucositis, Lymphoma, Multiple Myeloma, Hematologic Cancer
- Trial name
- Capella (NCT05493800)
- Testing
- MIT-001, normal saline
- Where
- 2 sites in South Korea
- Volunteers
- 60 people
- Sponsor
- MitoImmune Therapeutics
Sialorrhea Secondary to Parkinson's Disease
Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients
The primary goal of the study is to evaluate the safety and potential efficacy of intra-oral dissolvable NH004 films to improve the short-term symptoms of sialorrhea (drooling) in Parkinson's disease (PD) patients.
- Trial name
- NH004-2 (NCT00761137)
- Testing
- 0.3 mg tropicamide, 1 mg tropicamide, 3 mg tropicamide
- Where
- Argentina
- Volunteers
- 19 people
- Sponsor
- NeuroHealing Pharmaceuticals Inc.
Parotid Diseases
Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery
The objective of the clinical trial is to determine the suitability of the FMwand Ferromagnetic Surgical System for parotidectomy and Head \& Neck surgery.
- Trial name
- NCT02291939
- Testing
- Parotidectomy
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- Domain Surgical, Inc.
Orofacial Myofunctional Disorders, Myo Munchee
Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).
Multi-center, 6-month, randomized, and controlled trial to compare the effects of Myo Munchee therapy and Oral Motor Therapy (OMT) in pediatric patients (aged 3-5 years) to treat maxillary deficiency and orofacial myofunctional…
- Conditions
- Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
- Trial name
- NCT07088055
- Testing
- Chewing device only, Myo Munchee and Oral Motor Therapy Treatment, Oral Motor Therapy Treatment Arm
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Myo Munchee (Operations) Pty Ltd
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.